Nan Fung Group Sells $4.3 Million Worth of Oculis Shares Amid Drug Trial Setback
Nan Fung Group Holdings Ltd sold $4.3 million in shares of clinical-stage biopharmaceutical company Oculis during Q1 2026, following the failure of its lead drug's Phase 3 trial for diabetic macular edema. The sale reduced Nan Fung’s stake to approximately 7.7% of its total AUM.
Tickers: $OCS